Objective: the hyoscine-n-butylbromide (Buscopan) is ought to be avoided during colonoscopy in patients with a history of angle-closure glaucoma. Angle-closure glaucoma, nonetheless, is not very common, is asymptomatic before onset and is treated definitively by a single laser treatment (if spotted early). Open-angle glaucoma is not affected by hyoscine. Purpose: the purpose of this study was to evaluate the use of hyoscine amid colonoscopists, with certain reference to glaucoma. Materials and Methods: a short questionnaire was electronically managed to members of the Saudi Society of Gastroenterology and the Association of Coloproctology of KSA. The use of Hyoscine among colonoscopists and the effect of glaucoma history upon the prescribing practice. Results: sixty-three colonoscopists responded to some or all of the questions. 41/61 (67.2%) of respondents claimed they were aware of the guidelines. 53/62 (85.5%) sometimes or always use hyoscine, while 9/62 (14.5%) never do. 45/59 (76.3%) always enquire about glaucoma history prior to administration, even though 48/58 (82.8%) make no differentiation between open-angle or angle-closure forms. 42/59 (71.2%) would (incorrectly) withhold hyoscine if the patient declares a history of any form of glaucoma. 46/59 (78.2%) do not substitute glucagon as an antispasmodic. 2/60 (3.3%) had encountered ophthalmic complications post-administration. Conclusions: current guidelines pertaining to hyoscine use and glaucoma are inappropriate. Patients undergoing colonoscopy who have received hyoscine should, instead, be advised to seek urgent medical advice if they develop ophthalmic symptoms.